Red Osmo | Centro de Investigacion Medica Aguascalientes

Research site

(Unclaimed)

Location

Avenida Independencia 2130 Trojes de Alonso, Aguascalientes, Aguascalientes, Mexico

Site insights

Top conditions

Top treatments

Galcanezumab

LY573144

Lasmiditan

MK-8835-059

Estrogen

MK-4482

Giredestrant

Ertugliflozin

BMS-986278

LY3298176

Parent organization

This site is a part of Red Osmo

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 13 total trials

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with phy...

Active, not recruiting

Early Breast Cancer

Drug: LHRH Agonist

Drug: Giredestrant

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Active, not recruiting

Chronic Migraine

Drug: Placebo

Drug: Galcanezumab

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Active, not recruiting

Episodic Migraine

Drug: Galcanezumab

Drug: Placebo

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Active, not recruiting

Progressive Pulmonary Fibrosis

Drug: BMS-986278 Placebo

Drug: BMS-986278

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to pr...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Biological: Pembrolizumab

Biological: Sacituzumab Govitecan

VE303 for Prevention of Recurrent Clostridioides Difficile Infection (RESTORATiVE303)

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week...

Enrolling

CDI

C.Difficile Diarrhea

Biological: Placebo

Biological: VE303